From the Journals

Childhood adiposity tied to NAFLD and elevated ALT in adulthood


 

Overweight or obese children in a cohort study were more likely to have adult nonalcoholic fatty liver disease (NAFLD) and elevated levels of the liver enzyme alanine aminotransferase than were healthy weight children of both sexes, but this association can be mitigated by weight loss in adulthood.

“These findings underscore the importance of both early prevention and lifelong treatment of overweight and obesity to reduce the risk of adverse liver outcome in adulthood,” Yinkun Yan, PhD, an epidemiologist at the Capital Institute of Pediatrics, Beijing, and associates wrote (Pediatrics. 2017;139[4]:e20162738).

Overweight child eating lunch ©SolStock/iStock
The investigators examined data for 1,350 children (aged 6-18 years) from the Beijing Blood Pressure Cohort Study, begun in 1987 and 1988 to learn about precursors of adult cardiovascular diseases. The participants underwent health examinations between 2010 and 2014, at ages 28-45 years, after 23 years of follow-up.

The adiposity of the children was determined by caliper measurements and body mass index. ALT elevation was diagnosed via blood tests and NAFLD from ultrasonography. ALT is considered to be the most specific marker of liver damage, and NAFLD is one of the most common causes of liver disease worldwide.

Children who were overweight or obese were more likely to grow up to have elevated ALT levels (40% vs. 30% in men and 23% vs. 12% in women) or NAFLD (62% vs. 39% in men and 39% vs. 15% in women) than were healthy weight children. Obesity in adulthood was a higher risk whether a participant was obese as a child or not, but the researchers noted that risks could be mitigated by acquiring normal weight in adulthood.

Recommended Reading

The Liver Meeting 2016 debrief – key abstracts
MDedge Endocrinology
Nonalcoholic fatty liver disease accelerates brain aging
MDedge Endocrinology
VIDEO: Angiogenesis has a role to play in NASH and NAFLD
MDedge Endocrinology
Mild, moderate hypertriglyceridemia raises pancreatitis risk
MDedge Endocrinology
VIDEO: NAFLD costing U.S. $290 billion annually
MDedge Endocrinology
Cabozantinib shows promise for carcinoid tumors, pNET
MDedge Endocrinology
Rapid deterioration of type 2 diabetes may be marker for early pancreatic cancer
MDedge Endocrinology
‘Strong evidence’ links obesity to cancers
MDedge Endocrinology
Humira Pen topped per-person drug spending in 2016
MDedge Endocrinology
Liver disease likely to become increasing indication for bariatric surgery
MDedge Endocrinology